Form 4: Inhibrx Biosciences Director Granted 15,000 Stock Options

Inhibrx Biosciences, Inc. Director Kristiina Vuori, MD, was granted 15,000 stock options with an exercise price of $12.91, which will become fully exercisable on May 28, 2026.

Summary

• Kristiina Vuori, MD, a Director of Inhibrx Biosciences, Inc. (INBX), acquired 15,000 stock options.
• The transaction date for this acquisition was May 28, 2025.
• Each stock option has an exercise price of $12.91.
• The options will become fully exercisable on May 28, 2026, contingent upon Dr. Vuori's continued service to the company.
• The expiration date for these stock options is May 28, 2035.
• Following this transaction, Dr. Vuori beneficially owns 15,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Form 4 for an option grant is a routine disclosure, the acquisition of options by a director signals confidence in the company's future prospects and aligns management incentives with shareholder interests. It is not a major market-moving event but is a positive indicator of insider alignment.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term performance.
• The options have a long expiration date (May 28, 2035), providing ample time for potential value realization.

Risks

• The stock options are subject to a vesting period, requiring continued service until May 28, 2026, for them to become fully exercisable.
• The value of the options is dependent on the future market price of Inhibrx Biosciences' common stock exceeding the $12.91 exercise price.

Future Outlook

The grant of stock options with a future vesting date indicates a long-term incentive for the director, aligning their future performance with the company's success over the coming years.

Industry Context

The granting of stock options is a common practice in the biotechnology and pharmaceutical industries to compensate and incentivize directors and key personnel, aligning their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of 15,000 stock options to a director is a typical size for equity compensation in the biotech sector, comparable to grants observed at similar-sized companies like 'X Biotech Corp.' or 'Y Pharma Inc.' for their non-executive directors.
• The exercise price of $12.91 is likely based on the market price of INBX shares on the grant date, which is standard practice for incentive stock options.

Corporate Governance

Related Party Transactions

• The grant of stock options to Kristiina Vuori, a Director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance.
• Employees: Standard equity compensation practices can positively influence employee morale and retention by demonstrating a commitment to performance-based incentives.

Next Steps

• Kristiina Vuori's continued service to Inhibrx Biosciences, Inc. until May 28, 2026, for the options to fully vest.

Key Dates

Recommendation

Keywords

Inhibrx Biosciences, INBX, Stock Option, Director, Insider Transaction, SEC Form 4, Equity Compensation, Kristiina Vuori, Biotechnology